TP53 and neoplasm: A multivariate model including age, sex, primary tumor location, ECOG status, metastatic site, TMB, and APC (OMIM 611731), RAS, BRAF V600E, and TP53 (OMIM 191170) alterations maintained that liver metastases at the time of treatment initiation was the most significant factor associated with worse PFS (HR, 7.00; 95% CI, 3.18-15.42; P < .001).